Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Operating Income (2018 - 2025)

Entera Bio has reported Operating Income over the past 8 years, most recently at -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 29.61% year-over-year to -$3.0 million, compared with a TTM value of -$11.5 million through Dec 2025, down 20.15%, and an annual FY2025 reading of -$11.5 million, down 20.28% over the prior year.
  • Operating Income came in at -$3.0 million for Q4 2025, up from -$3.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$2.0 million in Q4 2023 to a low of -$4.1 million in Q4 2021.
  • Median Operating Income over the past 5 years was -$2.6 million (2021), compared with a mean of -$2.8 million.
  • The largest YoY upside for Operating Income was 79.57% in 2021 against a maximum downside of 233.28% in 2021.
  • Over 5 years, Operating Income stood at -$4.1 million in 2021, then rose by 24.95% to -$3.1 million in 2022, then surged by 36.02% to -$2.0 million in 2023, then dropped by 19.05% to -$2.3 million in 2024, then fell by 29.61% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Operating Income are -$3.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.7 million (Q2 2025).